| HCA |
Report |
Operating diluted EPS |
BEAT |
pred ~$7.59 vs. cons $7.45 (Visible Alpha, May 1) |
HIGH |
| HCA |
Report |
Revenue |
BEAT |
pred ~$20.23B vs. cons $19.36B (Visible Alpha, May 1) |
HIGH |
| HCA |
Report |
Adjusted EBITDA |
BEAT |
pred ~$4.03B vs. cons $3.97B (Visible Alpha, May 1) |
HIGH |
| HCA |
Guide |
FY26 revenue |
UNCHANGED |
guide ~$78.25B midpoint vs. cons $78.44B |
MEDIUM |
| HCA |
Guide |
FY26 adjusted EBITDA |
UNCHANGED |
guide ~$15.75B midpoint vs. cons $15.84B |
MEDIUM |
| HCA |
Guide |
FY26 diluted EPS |
UNKNOWN |
guide $28.70-$30.50 vs. $30.00 operating-EPS consensus; basis mismatch |
LOW |
| HCA |
Guide |
Exchange/surgical commentary |
UNKNOWN |
reaffirm exchange-impact range and continued mix pressure; no reliable consensus |
MEDIUM |
| HCA |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.0% |
— |
LOW |
| HCA |
Return |
5-day cumulative residual |
+1.0% (STABILIZE) |
STABILIZE — preannouncement already absorbed the principal estimate reset |
LOW |